Lrig-1 Antibody Targeting for Specific Treg Cell Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack specific targets for regulatory T cells (Treg cells) to address autoimmune and metabolic diseases, as existing markers like CD25, CTLA4, CD62L, CD38, CD103, and CD45RB are not sufficient for effective therapeutic intervention.
Innovation Solution
Development of antibodies or antigen-binding fragments that specifically bind to the Lrig-1 protein, a transmembrane protein on Treg cells, targeting epitopes such as those represented by SEQ ID NOs: 35 to 45, which can be used in pharmaceutical compositions, diagnostic kits, and antibody-drug conjugates to regulate Treg cell function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing marker substances (CD25, CTLA4, CD62L, CD38, CD103, GITR, CD45RB) are used to target regulatory T cells, then some level of Treg cell recognition is achieved, but specific targeting of regulatory T cells alone is not sufficient for effective therapeutic intervention
Solution Approach 1:
The patent extracts and isolates Lrig-1 as a specific marker substance from the complex mixture of Treg cell surface proteins. By focusing on this single, highly specific marker that is uniquely expressed on regulatory T cells, the invention enables precise targeting of Treg cells without the cross-reactivity issues associated with using conventional markers that are also expressed on other cell types.
Solution Approach 2:
The invention applies the principle of local quality by identifying Lrig-1 as a marker with distinctive expression patterns specifically localized to regulatory T cells. This localized expression pattern allows for differentiated targeting - antibodies against Lrig-1 will specifically bind to Treg cells while leaving other cell types unaffected, enabling cell-type-specific therapeutic interventions.
2Adaptability or versatility
If conventional T cell markers are used for therapeutic intervention, then broad T cell modulation is achieved, but specific regulation of regulatory T cell function cannot be accomplished
Solution Approach 1:
The patent introduces Lrig-1 as an intermediary marker that mediates specific recognition and modulation of regulatory T cells. By using Lrig-1 as the target, therapeutic antibodies can specifically interact with Treg cells to modulate their function without requiring complex combination therapies or multiple markers, thereby simplifying the therapeutic strategy while achieving adaptable Treg cell modulation.
3Measurement precision
If multiple marker substances are combined to improve Treg cell targeting, then recognition accuracy may improve, but the complexity and cost of therapeutic composition increases
Solution Approach 1:
The patent extracts Lrig-1 as a single, sufficient marker for accurate Treg cell recognition. By demonstrating that Lrig-1 alone provides the necessary specificity and accuracy for Treg cell targeting, the invention eliminates the need to combine multiple markers, thereby simplifying the pharmaceutical composition while maintaining high recognition accuracy.
Solution Approach 2:
The invention establishes Lrig-1 as a universal marker that can serve multiple functions: specific Treg cell identification, therapeutic targeting, and diagnostic applications. This multi-functionality of a single marker simplifies the overall therapeutic approach compared to using multiple specialized markers for different functions.
Data Source
Figure 1~2
Figure 3
Figure 4~5
AI summary
The present invention relates to an epitope of Lrig1 (leucine-rich and immunoglobulin-like domains protein 1) protein, which is an antigen present on the surface of regulatory T cells, and to an antibody or an antigen-binding fragment that specifically binds thereto. The present invention also provides compositions for diagnosis of metabolic diseases, diagnostic kits, methods of providing information for diagnosis, or diagnostic devices comprising as an active ingredient an antibody or antigen-binding fragment capable of specifically binding to Lrig-1 (leucine-rich and immunoglobulin-like domains 1) protein present on the surface of regulatory T cells or adipocytes.